Correction: Whole-Exome Sequencing Identifies Homozygous AFG3L2 Mutations in a Spastic Ataxia-Neuropathy Syndrome Linked to Mitochondrial m-AAA Proteases

Autor: Tm, Pierson, Adams D, Bonn F, Martinelli P, Pf, Cherukuri, Jk, Teer, Nf, Hansen, Cruz P, Jc, Mullikin, Rw, Blakesley, Golas G, Kwan J, Sandler A, Fuentes Fajardo K, Markello T, Tifft C, Blackstone C, Elena Rugarli, Langer T, Wa, Gahl, Toro C

Publikováno v: PLoS Genetics, Vol 9, Iss 2 (2013)
Europe PubMed Central
PLoS Genetics

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b6e39d43197f3b932960591f153132
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586582/?tool=EBI

Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma.

Autor: Permuth JB; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Park MA; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States., Chen DT; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States., Basinski T; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Powers BD; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.; Department of Surgery, School of Medicine, University of Maryland, Baltimore, MD, United States., Gwede CK; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States., Dezsi KB; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States., Gomez M; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Vyas SL; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.; Research Analytics and Development Cores, Baylor Scott & White Research Institute (BSWRI), Dallas, TX, United States., Biachi T; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Cortizas EM; Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States., Crowder S; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States., Genilo-Delgado M; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Green BL; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States., Greene A; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States., Gregg C; Department of Neurobiology, School of Medicine, University of Utah Health, Salt Lake City, UT, United States., Hoffe SE; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Jiang K; Department of Pathology, Moffitt Cancer Center, Tampa, FL, United States., Kim B; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Vasudevan V; Center for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, United States., Garcialopez De Llano J; Center for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, United States., Menon AA; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Mo Q; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States., MorenoUrazan LM; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Mok S; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Parker N; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States., Rajasekhara S; Supportive Care Medicine, Moffitt Cancer Center, Tampa, FL, United States., Rasool G; Department of Machine Learning, Moffitt Cancer Center, Tampa, FL, United States., Sinnamon A; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States., Sparks L; Translational Research Institute, AdventHealth, Orlando, FL, United States., Stewart PA; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States., Tardif K; Department of Surgery, St. Anthony's Hospital, St. Petersburg, FL, United States., Tassielli AF; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Teer JK; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States., Tran DV; Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States., Turner KL; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States., Vadaparampil ST; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.; Community Outreach, Engagement & Equity, Moffitt Cancer Center, Tampa, FL, United States., Whelan CJ; Department of Metabolism and Cancer Physiology, Moffitt Cancer Center, Tampa, FL, United States., Douglas WG; Department of Clinical Sciences, College of Medicine, Florida State University, Tallahassee, FL, United States., Velanovich V; Tampa General Hospital, Tampa, FL, United States., Karachristos A; Tampa General Hospital, Tampa, FL, United States., Legaspi A; Center for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, United States., Meredith K; Department of Gastrointestinal Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, United States., Molina-Vega MA; Department of Surgical Oncology, Lakeland Regional Hospital, Lakeland, FL, United States., Huguet KL; Department of Surgery, St. Anthony's Hospital, St. Petersburg, FL, United States., Arnoletti JP; Department of Surgical Oncology, Orlando Regional Medical Center, Orlando, FL, United States., Bloomston M; Department of Surgical Oncology, Lee Health Regional Cancer Center, Fort Myers, FL, United States., Trevino J; Department of Surgery, College of Medicine, University of Florida, Gainesville, FL, United States.; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States., Merchant NB; Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States., Pimiento JM; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Hodul PJ; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Malafa M; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Fleming J; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States., Judge SM; Department of Physical Therapy, College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States., Jeong DK; Supportive Care Medicine, Moffitt Cancer Center, Tampa, FL, United States., Judge A; Department of Physical Therapy, College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2024 Jul 23; Vol. 14, pp. 1362244. Date of Electronic Publication: 2024 Jul 23 (Print Publication: 2024).

Lung adenocarcinomas without driver genes converge to common adaptive strategies through diverse genetic, epigenetic, and niche construction evolutionary pathways.

Autor: Gatenby RA; Department of Cancer Biology and Evolution, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA. Robert.gatenby@moffitt.org., Luddy KA; Department of Cancer Biology and Evolution, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA., Teer JK; Department of Cancer Biology and Evolution, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA.; Department of Bioinformatics, Moffitt Cancer Center, Tampa, USA., Berglund A; Department of Cancer Biology and Evolution, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA.; Department of Bioinformatics, Moffitt Cancer Center, Tampa, USA., Freischel AR; Cancer Bioengineering Department, University of Texas, Austin, USA., Carr RM; Department of Oncology, Mayo Clinic, Rochester, USA., Lam AE; Case Western Reserve University, Cleveland, USA., Pienta KJ; Cancer Ecology Program, Johns Hopkins University, Baltimore, USA., Amend SR; Cancer Ecology Program, Johns Hopkins University, Baltimore, USA., Austin RH; Department of Physics, Princeton University, Princeton, USA., Hammarlund EU; Division of Translational Cancer Research, Lund University, Lund, Sweden., Cleveland JL; Department of Cancer Biology and Evolution, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA., Tsai KY; Departments of Pathology and Tumor Biology, Moffitt Cancer Center, Tampa, USA., Brown JS; Department of Cancer Biology and Evolution, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA.

Publikováno v: Medical oncology (Northwood, London, England) [Med Oncol] 2024 May 05; Vol. 41 (6), pp. 135. Date of Electronic Publication: 2024 May 05.

Genomic Classification and Individualized Prognosis in Multiple Myeloma.

Autor: Maura F; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Rajanna AR; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Ziccheddu B; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Poos AM; Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Derkach A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Maclachlan K; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Durante M; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Diamond B; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Papadimitriou M; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Davies F; Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY., Boyle EM; Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY., Walker B; Division of Hematology Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN., Hultcrantz M; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Silva A; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Hampton O; Aster Insights, Tampa, FL., Teer JK; Department of Biostatistics & Bioinformatics, Moffitt Cancer Center & Research Institute, Tampa, FL., Siegel EM; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL., Bolli N; Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy., Jackson GH; Freeman Hospital, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom., Kaiser M; The Institute of Cancer Research, London, United Kingdom., Pawlyn C; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Cook G; Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA., Kazandjian D; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Stein C; Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA., Chesi M; Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA., Bergsagel L; Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA., Mai EK; Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Goldschmidt H; Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Weisel KC; Department of Oncology, Hematology and Blood and Marrow Transplant, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Fenk R; Department of Hematology, Oncology and Clinical Immunology, University-Hospital Duesseldorf, Duesseldorf, Germany., Raab MS; Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Van Rhee F; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR., Usmani S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Shain KH; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Weinhold N; Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Morgan G; Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY., Landgren O; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 10; Vol. 42 (11), pp. 1229-1240. Date of Electronic Publication: 2024 Jan 09.

Association between CYP3A4 , CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients.

Autor: Ho TT; Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL 33612, USA.; Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Perkins JB; Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL 33612, USA., Gonzalez R; Department of Blood & Marrow Transplant & Cellular Immunotherapy (BMT CI), H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Pharmacy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Hicks JK; Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Martinez RA; Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL 33612, USA., Duranceau K; Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL 33612, USA., North B; Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL 33612, USA., Kim J; Department of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Teer JK; Department of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Yao J; Department of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Yoder SJ; Molecular Genomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Nishihori T; Department of Blood & Marrow Transplant & Cellular Immunotherapy (BMT CI), H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Bejanyan N; Department of Blood & Marrow Transplant & Cellular Immunotherapy (BMT CI), H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Pidala J; Department of Blood & Marrow Transplant & Cellular Immunotherapy (BMT CI), H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Elmariah H; Department of Blood & Marrow Transplant & Cellular Immunotherapy (BMT CI), H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

Publikováno v: Pharmacogenomics [Pharmacogenomics] 2024 Jan; Vol. 25 (1), pp. 29-40. Date of Electronic Publication: 2024 Jan 08.